Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma
In this economic evaluation, conducted alongside a randomized, double-blind clinical trial, economic data were collected from 339 patients with moderate-persistent asthma randomized to receive twice-daily, double-blind treatment with budesonide/formoterol 160/4.5 μg in a single inhaler (n = 166) or fluticasone propionate 250 μg (n = 173) for 12 weeks. The mean number of episode-free days (EFD) per
